Cita APA (7a ed.)

Li, J., Yue, H., Li, W., Zhu, G., Zhu, T., Chen, R., & Lu, X. (2021). Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression. BMC.

Cita Chicago Style (17a ed.)

Li, Jun, Huiran Yue, Wenzhi Li, Guohua Zhu, Tingting Zhu, Ruifang Chen, y Xin Lu. Bevacizumab Confers Significant Improvements in Survival for Ovarian Cancer Patients with Low MiR-25 Expression and High MiR-142 Expression. BMC, 2021.

Cita MLA (8a ed.)

Li, Jun, et al. Bevacizumab Confers Significant Improvements in Survival for Ovarian Cancer Patients with Low MiR-25 Expression and High MiR-142 Expression. BMC, 2021.